Nuvectis Pharma
NVCTNVCT · Stock Price
Historical price data
Overview
Nuvectis Pharma is a clinical-stage oncology company focused on developing innovative, targeted small molecules for serious cancers with limited treatment options. Its lead asset, NXP900, is a first-in-class Type 1.5 SRC/YES1 inhibitor designed to completely shut down oncogenic signaling, while NXP800 represents a novel approach via GCN2 activation. The company's strategy centers on precision medicine, advancing programs through clinical proof-of-concept with a lean, experienced team that has a proven track record of guiding drugs to market. Nuvectis is publicly traded on NASDAQ under the ticker NVCT.
Technology Platform
Nuvectis focuses on developing targeted small molecules with novel mechanisms of action, exemplified by NXP900's Type 1.5 SRC/YES1 inhibition and NXP800's GCN2 activation, applying a precision medicine approach to select patient populations.
Pipeline
3| Drug | Indication | Stage | Watch |
|---|---|---|---|
| NXP900 + Osimertinib | EGFR Mutation Positive Non-small Cell Lung Cancer | Phase 1 | |
| NXP900 | Advanced Solid Tumor | Phase 1 | |
| NXP800 | Advanced Solid Tumor | Phase 1 |
Funding History
2Opportunities
Risk Factors
Competitive Landscape
NXP900 faces competition from historical SRC inhibitors and new clinical-stage selective agents, requiring it to demonstrate a superior therapeutic index. NXP800 operates in a novel target space (HSF1/GCN2) with no direct competitors but faces indirect competition from other therapies in its target indications, such as PARP inhibitors and ADCs in ovarian cancer.